🧬 SinoBioData Academic Portal
Open AccessDOI: 10.3724/abbs.2024050Original Research

GroEL triggers NLRP3 inflammasome activation through the TLR/NF-κB p-p65 axis in human periodontal ligament stem cells

🇨🇳 Original Chinese Title: GroEL triggers NLRP3 inflammasome activation through the TLR/NF-κB p-p65 axis in human periodontal ligament stem cells

Li Zhang¹,Mengmeng Duan¹,Xiaohua Pu¹,Huiling Zheng¹,Xinjie Ning¹,Ying Tu¹,Chunming Xu¹,Demao Zhang¹,Chengcheng Liu¹,Jing Xie¹

State Key Laboratory of Oral Diseases & National Center for Stomatology & National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China

Read Executive PreviewQuick FAQ
GroEL triggers NLRP3 inflammasome activation through the TLR/NF-κB p-p65 axis in human periodontal ligament stem cells
Graphical Abstract / Figure
Published In
Acta Biochimica et Biophysica Sinica
Published:2024Edition:Vol. 56, Issue 9 • pp. 1340-1351Citation:Li Zhang et al. (2024), Acta Biochimica et Biophysica Sinica
Impact FactorPremier Chinese Biomedical Journal indexed in SinoBioData: Acta Biochimica et Biophysica Sinica (生物化学与生物物理学报).
Sponsored Research Partner

Key Takeaways & Executive Findings

  • • GroEL from oral pathogens activates the NLRP3 inflammasome in human periodontal ligament stem cells, leading to IL-1β and IL-18 secretion and ECM degradation via MMP-2/9. • The activation is dependent on TLR2 and TLR4, which upregulate NF-κB (p-p65) signaling and nuclear accumulation. • In vivo rat model confirms that GroEL injection induces similar inflammatory responses, validating the in vitro findings. • This study identifies GroEL as a key virulence factor in periodontitis pathogenesis and suggests potential therapeutic targets (TLR/NF-κB/NLRP3 axis) for prevention.
Sponsored Research Highlight

Abstract

The interaction between bacteria and the host plays a vital role in the initiation and progression of systemic diseases, including gastrointestinal and oral diseases, due to the secretion of various virulence factors from these pathogens. GroEL, a potent virulence factor secreted by multiple oral pathogenic bacteria, is implicated in the damage of gingival epithelium, periodontal ligament, alveolar bone and other peripheral tissues. However, the underlying biomechanism is still largely unknown. In the present study, we verify that GroEL can trigger the activation of NLRP3 inflammasome and its downstream effector molecules, IL-1β and IL-18, in human periodontal ligament stem cells (hPDLSCs) and resultantly induce high activation of gelatinases (MMP-2 and MMP-9) to promote the degradation of extracellular matrix (ECM). GroEL-mediated activation of the NLRP3 inflammasome requires the participation of Toll-like receptors (TLR2 and TLR4). High upregulation of TLR2 and TLR4 induces the enhancement of NF-κB (p-p65) signaling and promotes its nuclear accumulation, thus activating the NLRP3 inflammasome. These results are verified in a rat model with direct injection of GroEL. Collectively, this study provides insight into the role of virulence factors in bacteria-induced host immune response and may also provide a new clue for the prevention of periodontitis.

1. Introduction

Periodontitis, a microbiome-driven chronic inflammatory disease, occurs in periodontal tissue and can lead to persistent destruction of periodontal tissue and eventually tooth loss [1,2]. Severe periodontitis is the sixth most prevalent disease worldwide and affects approximately 10% of adults globally [3]. In addition, periodontitis is closely related to the occurrence and development of systemic diseases, such as diabetes, cardiovascular disease, Alzheimer's disease and rheumatoid joints [1,4,5]. Pathogenic bacteria in subgingival plaques are a precondition for periodontitis [6,7]. Pathogenic bacteria and their microbial virulence factors, such as lipopolysaccharide (LPS), proteases, GroEL and lipoteichoic acid, stimulate host cells to produce inflammatory factors and enzymes, which in turn contribute to the destruction of periodontal tissues [8].

Bacterial GroEL, a member of the heat shock protein (HSP) family, is highly homologous to human HSP60 and plays an important role in the proper folding and translocation of proteins during protein synthesis, as well as in the recombination of denatured proteins [9,10]. Nonetheless, GroEL has also been reported to play a pathogenic role in a variety of bacterial infectious diseases and autoimmune diseases [11‒13]. Our previous study revealed that GroEL levels in gingival crevicular fluid and saliva were higher in patients with apical periodontitis than in healthy individuals [14]. A previous study based on clinical investigation reported that salivary immunoglobulin A (IgA) has immunoreactivities with Porphyromonas gingivalis (P. gingivalis) GroEL and Campylobacter rectus (C. rectus) GroEL, and its level is correlated with the severity of periodontal disease [15]. Another study reported that elevated levels of anti-HSP60 antibodies were detected in the serum of cardiovascular patients with severe periodontitis [16]. Meanwhile, periodontal therapy could significantly reduce the GroEL expression level in serum derived from P. gingivalis [17]. Local injection of bacterial GroEL induces absorption of the skull in mice and alveolar bone in rats [11,18]. In addition, GroEL from Tannerella forsythia (T. forsythia) and C. rectus promotes the production of interleukin 6 and 8 in human gingival fibroblasts and periodontal ligament fibroblasts (hPDLFs) [11,19]. Lin et al. [20] reported that P. gingivalis GroEL induced the production of IL-6 and IL-8 in osteoblasts through p38/MAPK or JNK/MAPK signaling. Fusobacterium nucleatum (F. nucleatum) GroEL significantly upregulated the expressions of adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and E-selectin, as well as chemokines such as IL-8 and monocyte chemoattractant protein-1 (MCP-1), in human microvascular endothelial cells and enhanced the adhesion and migration of monocytes [21]. Previous evidence strongly suggested that GroEL may be a potential stimulator of periodontal disease. However, its virulent effect on periodontitis is not fully understood.

SinoBioData Interactive Document Reader
Page 1–5 of Preview
100%
Download Full PDF

Loading authentic research manuscript (Pages 1–5)...

Sponsored Research Partner
Cite This Research Paper
Li Zhang, Mengmeng Duan, Xiaohua Pu, Huiling Zheng, Xinjie Ning, Ying Tu, Chunming Xu, Demao Zhang, Chengcheng Liu, Jing Xie (2026). GroEL triggers NLRP3 inflammasome activation through the TLR/NF-κB p-p65 axis in human periodontal ligament stem cells. Acta Biochimica et Biophysica Sinica. https://doi.org/10.3724/abbs.2024050
SinoBioData Academic & Legal Disclaimer

Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.

Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.

Frequently Asked Questions

What is the role of GroEL in periodontitis?

GroEL, a virulence factor from oral bacteria, activates the NLRP3 inflammasome in human periodontal ligament stem cells, leading to inflammatory cytokine release and extracellular matrix degradation, contributing to periodontal tissue destruction.

How does GroEL activate the NLRP3 inflammasome?

GroEL upregulates TLR2 and TLR4, which enhance NF-κB (p-p65) signaling and nuclear accumulation, thereby activating the NLRP3 inflammasome and downstream IL-1β and IL-18 production.

What are the downstream effects of NLRP3 activation by GroEL?

Activation leads to increased secretion of IL-1β and IL-18, and upregulation of matrix metalloproteinases (MMP-2 and MMP-9), promoting degradation of the extracellular matrix in periodontal tissues.

Is the effect of GroEL confirmed in vivo?

Yes, direct injection of GroEL into a rat model reproduced the inflammatory responses observed in vitro, validating the role of GroEL in periodontitis pathogenesis.

What are potential therapeutic implications of this study?

Targeting the TLR/NF-κB/NLRP3 axis could provide new strategies for preventing or treating periodontitis by mitigating GroEL-induced inflammation and tissue destruction.

Recommended Scientific Literature & Research Partners

Related Technical Papers & Translations

Research Paper
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis

Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis

Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.

Read Abstract & PDF
Research Paper
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials

Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials

Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.

Read Abstract & PDF
Research Paper
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis

Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis

Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.

Read Abstract & PDF